PL2074122T3 - Związki pirydo(2,3-D)pirymidynonowe i ich zastosowanie jako inhibitory PI3 - Google Patents

Związki pirydo(2,3-D)pirymidynonowe i ich zastosowanie jako inhibitory PI3

Info

Publication number
PL2074122T3
PL2074122T3 PL07804890T PL07804890T PL2074122T3 PL 2074122 T3 PL2074122 T3 PL 2074122T3 PL 07804890 T PL07804890 T PL 07804890T PL 07804890 T PL07804890 T PL 07804890T PL 2074122 T3 PL2074122 T3 PL 2074122T3
Authority
PL
Poland
Prior art keywords
pyrido
inhibitors
compounds
Prior art date
Application number
PL07804890T
Other languages
English (en)
Polish (pl)
Inventor
Hengmiao Cheng
Dilip Bhumralkar
Klaus Ruprecht Dress
Jacqui Elizabet Hoffman
Mary Catherine Johnson
Robert Steven Kania
Phuong Thi Quy Le
Mitchell David Nambu
Mason Alan Pairish
Michael Bruno Plewe
Khanh Tuan Tran
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PL2074122T3 publication Critical patent/PL2074122T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
PL07804890T 2006-09-15 2007-09-03 Związki pirydo(2,3-D)pirymidynonowe i ich zastosowanie jako inhibitory PI3 PL2074122T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US84506506P 2006-09-15 2006-09-15
US94785207P 2007-07-03 2007-07-03
US95262807P 2007-07-30 2007-07-30
EP07804890.7A EP2074122B9 (en) 2006-09-15 2007-09-03 Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors
PCT/IB2007/002578 WO2008032162A1 (en) 2006-09-15 2007-09-03 Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors

Publications (1)

Publication Number Publication Date
PL2074122T3 true PL2074122T3 (pl) 2011-10-31

Family

ID=38859750

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07804890T PL2074122T3 (pl) 2006-09-15 2007-09-03 Związki pirydo(2,3-D)pirymidynonowe i ich zastosowanie jako inhibitory PI3

Country Status (41)

Country Link
US (3) US7696213B2 (enExample)
EP (1) EP2074122B9 (enExample)
JP (1) JP4718637B2 (enExample)
KR (1) KR101099926B1 (enExample)
CN (1) CN101573358B (enExample)
AP (1) AP2710A (enExample)
AR (1) AR062785A1 (enExample)
AT (1) ATE514695T1 (enExample)
AU (1) AU2007297212B8 (enExample)
BR (1) BRPI0716749B8 (enExample)
CA (1) CA2663401C (enExample)
CL (1) CL2007002682A1 (enExample)
CR (1) CR10662A (enExample)
CU (1) CU23783B7 (enExample)
CY (1) CY1111911T1 (enExample)
DK (1) DK2074122T5 (enExample)
DO (1) DOP2009000039A (enExample)
EA (1) EA016388B1 (enExample)
ES (1) ES2366489T3 (enExample)
GE (1) GEP20115306B (enExample)
GT (1) GT200700077A (enExample)
HN (1) HN2007000267A (enExample)
HR (1) HRP20110621T2 (enExample)
IL (1) IL197243A (enExample)
MA (1) MA30709B1 (enExample)
ME (1) MEP8009A (enExample)
MX (1) MX2009002927A (enExample)
MY (1) MY146420A (enExample)
NI (1) NI200900032A (enExample)
NO (1) NO342357B1 (enExample)
NZ (1) NZ575167A (enExample)
PE (1) PE20080670A1 (enExample)
PL (1) PL2074122T3 (enExample)
PT (1) PT2074122E (enExample)
RS (2) RS20090104A (enExample)
SI (1) SI2074122T1 (enExample)
TN (1) TN2009000085A1 (enExample)
TW (1) TWI334353B (enExample)
UY (1) UY30588A1 (enExample)
WO (1) WO2008032162A1 (enExample)
ZA (1) ZA200901477B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20115306B (enExample) 2006-09-15 2011-10-10 Pfizer Prod Inc
UA100979C2 (ru) * 2007-04-10 2013-02-25 Экселиксис, Инк. Применение пиридопиримидиноновых ингибиторов pi3k альфа для лечения рака
NZ579945A (en) * 2007-04-11 2012-05-25 Exelixis Inc Pyrido [2,3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
RU2508110C2 (ru) * 2008-07-11 2014-02-27 Новартис Аг КОМБИНАЦИЯ (А) ИНГИБИТОРА ФОСФОИНОЗИТ-3-КИНАЗЫ И (Б) МОДУЛЯТОРА ПУТИ Ras/Raf/Mek
TW201020238A (en) * 2008-08-20 2010-06-01 Schering Corp Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
US8470834B2 (en) 2008-08-20 2013-06-25 Merck Sharp & Dohme Corp. AZO-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
CA2734486A1 (en) 2008-08-20 2010-02-25 Southern Research Institute Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
AU2009282571B2 (en) 2008-08-20 2014-12-11 Merck Sharp & Dohme Corp. Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
AR073524A1 (es) * 2008-09-30 2010-11-10 Exelixis Inc Piridopirimidinonas inhibidores de pi3k a y m tor
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
CA2820078C (en) 2010-12-16 2019-02-12 F. Hoffmann-La Roche Ag Tricyclic pi3k inhibitor compounds and methods of use
US8664230B2 (en) * 2011-03-17 2014-03-04 The Asan Foundation Pyridopyrimidine derivatives and use thereof
TW201306842A (zh) * 2011-06-15 2013-02-16 Exelixis Inc 使用pi3k/mtor吡啶並嘧啶酮抑制劑及苯達莫司汀及/或利妥昔單抗治療惡性血液疾病之組合療法
MX2014002471A (es) 2011-08-31 2014-03-27 Novartis Ag Combinaciones sinergicas de los inhibidores de p13k y mek.
CN104829609B (zh) * 2014-02-11 2016-08-03 北大方正集团有限公司 取代的吡啶并嘧啶化合物及其制备方法和应用
WO2016015598A1 (en) 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof
CN105330699B (zh) * 2014-08-13 2018-12-04 山东汇睿迪生物技术有限公司 一种含磷吡啶并[2,3-d]嘧啶-7-酮类化合物或其药学上可接受的盐、药物组合物及其应用
JP6784668B2 (ja) 2014-10-10 2020-11-11 ファイザー・インク 相乗的オーリスタチン組合せ
HUE047477T2 (hu) 2015-06-04 2020-04-28 Pfizer Palbociclib szilárd dózisformái
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
ES3002745T3 (en) 2016-07-06 2025-03-07 Univ Michigan Regents Multifunctional inhibitors of mek/pi3k and mtor/mek/pi3k biological pathways and therapeutic methods using the same
JP6563623B1 (ja) 2016-08-15 2019-08-21 ファイザー・インク ピリドピリミジノンcdk2/4/6阻害剤
CA3045041A1 (en) * 2016-12-14 2018-06-21 Tarveda Therapeutics, Inc. Hsp90-targeting conjugates and formulations thereof
WO2019157516A1 (en) 2018-02-12 2019-08-15 resTORbio, Inc. Combination therapies
BR112020025283A2 (pt) 2018-06-15 2021-03-09 Navitor Pharmaceuticals, Inc. Análogos de rapamicina e usos dos mesmos
WO2020140055A1 (en) * 2018-12-28 2020-07-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
US20220220103A1 (en) * 2018-12-28 2022-07-14 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
US11583538B2 (en) 2019-04-08 2023-02-21 Venenum Biodesign, LLC Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors
AU2020397938A1 (en) 2019-12-05 2022-06-23 Janssen Pharmaceutica Nv Rapamycin analogs and uses thereof
WO2021139775A1 (zh) * 2020-01-10 2021-07-15 江苏先声药业有限公司 吡啶酮化合物及应用
WO2022075974A1 (en) * 2020-10-06 2022-04-14 Venenum Biodesign, LLC Cyclic trex1 inhibitors
JP2023549540A (ja) 2020-11-18 2023-11-27 デシフェラ・ファーマシューティカルズ,エルエルシー Gcn2およびperkキナーゼ阻害剤およびその使用方法
IL312844A (en) * 2021-11-18 2024-07-01 Onconova Therapeutics Inc Methods and compositions for treating cancer
JP2024544632A (ja) 2021-12-03 2024-12-03 デシフェラ・ファーマシューティカルズ,エルエルシー Gcn2及びperkキナーゼ阻害剤としての複素環式化合物
UY40772A (es) 2023-06-08 2024-12-31 Nimbus Wadjet Inc Inhibidores de wrn
WO2025137599A1 (en) * 2023-12-21 2025-06-26 Nimbus Wadjet, Inc. Wrn inhibitors

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264437A (en) * 1992-03-20 1993-11-23 Syntex (U.S.A.) Inc. Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones
RU2191188C2 (ru) 1994-11-14 2002-10-20 Варнер-Ламберт Компани Производные 6-арилпиридо[2,3-d]-пиримидины и -нафтиридины, фармацевтическая композиция, обладающая ингибирующим действием клеточной пролиферации, вызываемой протеиновой тирозинкиназой, и способ ингибирования клеточной пролиферации
CN1177960A (zh) * 1995-03-10 1998-04-01 圣诺菲药品有限公司 6-取代的吡唑并[3,4-d]嘧啶-4-酮及其组合物和使用方法
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US5925761A (en) 1997-02-04 1999-07-20 Sepracor Inc. Synthesis of terfenadine and derivatives
DE69839338T2 (de) 1997-02-05 2008-07-10 Warner-Lambert Company Llc Pyrido (2,3-d) pyrimidine und 4-amino-pyrimidine als inhibitoren der zellulären proliferation
US6498163B1 (en) * 1997-02-05 2002-12-24 Warner-Lambert Company Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
GB9904932D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy
CN1433417A (zh) 2000-01-27 2003-07-30 沃尼尔·朗伯公司 用于治疗神经变性疾病的吡啶并嘧啶酮衍生物
YU66502A (sh) 2000-03-06 2005-09-19 Warner-Lambert Company 5-alkilpirido(2,3-d)pirimidini, inhibitori tirozinkinaza
CN100345830C (zh) 2000-04-27 2007-10-31 安斯泰来制药有限公司 稠合杂芳基衍生物
JP4166991B2 (ja) 2001-02-26 2008-10-15 田辺三菱製薬株式会社 ピリドピリミジンまたはナフチリジン誘導体
US7019002B2 (en) * 2001-12-11 2006-03-28 Pharmacia & Upjohn, S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
DE60303009T2 (de) 2002-01-22 2006-07-13 Warner-Lambert Co. Llc 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-one
JP2003321472A (ja) 2002-02-26 2003-11-11 Takeda Chem Ind Ltd Grk阻害剤
MXPA04010267A (es) 2002-04-19 2005-02-03 Smithkline Beecham Corp Compuestos novedosos.
US20040063658A1 (en) 2002-05-06 2004-04-01 Roberts Christopher Don Nucleoside derivatives for treating hepatitis C virus infection
JP2004083587A (ja) 2002-08-06 2004-03-18 Tanabe Seiyaku Co Ltd 医薬組成物
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
JP2004203751A (ja) 2002-12-24 2004-07-22 Pfizer Inc 置換6,6−ヘテロ二環式誘導体
WO2004063195A1 (en) 2003-01-03 2004-07-29 Sloan-Kettering Institute For Cancer Research Pyridopyrimidine kinase inhibitors
WO2004089930A1 (en) 2003-04-02 2004-10-21 Imclone Systems Incorporated 4-fluoroquinolone derivatives and their use as kinase inhibitors
JP2007504283A (ja) 2003-05-20 2007-03-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア β−アミロイド斑に作用物質を結合させる方法
JP4053073B2 (ja) 2003-07-11 2008-02-27 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 選択的cdk4阻害剤のイセチオン酸塩
BRPI0412876A (pt) 2003-07-22 2006-10-03 Janssen Pharmaceutica Nv derivados de quinolinona como inibidores de c-fms quinase
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
CN1918158B (zh) 2004-02-14 2011-03-02 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
JP2007523151A (ja) 2004-02-18 2007-08-16 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 2−(ピリジン−3−イルアミノ)−ピリド[2,3−d]ピリミジン−7−オン
WO2005094830A1 (en) 2004-03-30 2005-10-13 Pfizer Products Inc. Combinations of signal transduction inhibitors
WO2005105097A2 (en) 2004-04-28 2005-11-10 Gpc Biotech Ag Pyridopyrimidines for treating inflammatory and other diseases
BRPI0510560A (pt) * 2004-05-04 2007-11-20 Warner Lambert Co pirido[2,3-d] pirimidin-7-onas pirrolil substituìdas e seus derivados como agentes terapêuticos
MXPA06014021A (es) 2004-06-04 2007-02-08 Pfizer Prod Inc Procedimiento para tratar crecimiento celular anormal.
CA2575804A1 (en) 2004-08-26 2006-03-02 Boehringer Ingelheim International Gmbh Pteridinones used as plk (polo like kinase) inhibitors
CA2585091C (en) 2004-11-03 2016-07-19 University Of Kansas Novobiocin analogues as anticancer agents
EP1828186A1 (en) 2004-12-13 2007-09-05 Sunesis Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors
US20060142312A1 (en) * 2004-12-23 2006-06-29 Pfizer Inc C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
US8044062B2 (en) * 2005-10-07 2011-10-25 Exelixis, Inc. Substituted pyrido[2,3-d]pyrimidin-7(8H)-one inhibitors of phospatidylinositol 3-kinase alpha
US8247408B2 (en) * 2005-10-07 2012-08-21 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer
EP1872922A1 (en) * 2006-06-27 2008-01-02 Nederlandse Organisatie voor Toegepast-Natuuurwetenschappelijk Onderzoek TNO Method and apparatus for manufacturing a polymeric article
JP2010500994A (ja) 2006-08-16 2010-01-14 エグゼリクシス, インコーポレイテッド Pi3kおよびmekモジュレーターを使用する方法
GEP20115306B (enExample) * 2006-09-15 2011-10-10 Pfizer Prod Inc
JP5577104B2 (ja) * 2007-03-14 2014-08-20 エクセリクシス パテント カンパニー エルエルシー ヘッジホッグ経路の阻害剤
NZ579945A (en) * 2007-04-11 2012-05-25 Exelixis Inc Pyrido [2,3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
AR073524A1 (es) * 2008-09-30 2010-11-10 Exelixis Inc Piridopirimidinonas inhibidores de pi3k a y m tor
WO2011130628A1 (en) * 2010-04-16 2011-10-20 Curis, Inc. Treatment of cancers having k-ras mutations

Also Published As

Publication number Publication date
US7696213B2 (en) 2010-04-13
RS20090104A (sr) 2010-06-30
CU20090040A7 (es) 2011-07-11
NO20091141L (no) 2009-03-31
CU23783B7 (es) 2012-02-15
WO2008032162A8 (en) 2009-03-26
US20100137279A1 (en) 2010-06-03
BRPI0716749B8 (pt) 2021-05-25
WO2008032162A1 (en) 2008-03-20
IL197243A0 (en) 2009-12-24
ES2366489T9 (es) 2013-12-27
US8633204B2 (en) 2014-01-21
SI2074122T1 (sl) 2011-10-28
IL197243A (en) 2013-07-31
BRPI0716749B1 (pt) 2020-10-06
CY1111911T1 (el) 2015-11-04
HN2007000267A (es) 2011-02-25
CA2663401C (en) 2011-07-12
JP2010503653A (ja) 2010-02-04
AP2710A (en) 2013-07-30
CN101573358B (zh) 2012-05-30
AR062785A1 (es) 2008-12-03
CL2007002682A1 (es) 2008-04-04
MA30709B1 (fr) 2009-09-01
HRP20110621T1 (hr) 2011-09-30
KR20090040389A (ko) 2009-04-23
DK2074122T3 (da) 2011-08-15
EP2074122B9 (en) 2013-09-11
US20080090801A1 (en) 2008-04-17
PT2074122E (pt) 2011-08-24
MX2009002927A (es) 2009-03-31
DOP2009000039A (es) 2015-12-15
CA2663401A1 (en) 2008-03-20
TWI334353B (en) 2010-12-11
PE20080670A1 (es) 2008-06-14
ZA200901477B (en) 2010-07-28
BRPI0716749A2 (pt) 2014-02-18
US8273755B2 (en) 2012-09-25
EA200970207A1 (ru) 2009-08-28
JP4718637B2 (ja) 2011-07-06
EP2074122B1 (en) 2011-06-29
MY146420A (en) 2012-08-15
AU2007297212A1 (en) 2008-03-20
ATE514695T1 (de) 2011-07-15
GEP20115306B (enExample) 2011-10-10
MEP8009A (en) 2011-12-20
EP2074122A1 (en) 2009-07-01
EA016388B1 (ru) 2012-04-30
ES2366489T3 (es) 2011-10-20
US20120309775A1 (en) 2012-12-06
UY30588A1 (es) 2008-05-02
GT200700077A (es) 2009-08-03
CR10662A (es) 2009-04-17
AU2007297212B8 (en) 2011-04-28
TW200820972A (en) 2008-05-16
AP2009004790A0 (en) 2009-04-30
DK2074122T5 (da) 2014-03-17
HK1138589A1 (en) 2010-08-27
RS51927B (sr) 2012-02-29
TN2009000085A1 (fr) 2010-08-19
NZ575167A (en) 2010-10-29
AU2007297212B2 (en) 2011-04-14
CN101573358A (zh) 2009-11-04
KR101099926B1 (ko) 2011-12-28
NO342357B1 (no) 2018-05-14
HRP20110621T2 (hr) 2013-12-06
NI200900032A (es) 2010-05-14

Similar Documents

Publication Publication Date Title
PT2074122E (pt) Compostos de pirido(2,3-d)-pirimidinona e sua utilização como inibidores de pi3
IL198509A0 (en) Azaindole derivatives, compositions containing the same and uses thereof
IL210821A0 (en) Pyrazolopyridine kinase inhibitor compounds, compositions comprising the same and uses thereof
IL198250A0 (en) Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b
ZA201004524B (en) Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
EP1993539A4 (en) THIAZOLONE AS A PI3 KINASE INHIBITOR
IL201836A0 (en) Pyrrolopyridine derivatives and their use as bace inhibitors
PL2094263T3 (pl) Pochodne 2-adamantylo-butyroamidowe jako selektywne inhibitory 11beta-HSD1
IL184901A0 (en) 2,4-diamino-pyridopyrimidine derivatives and their use as mtor inhibitors
ZA200909152B (en) Triazolopyridine compounds and their use as ask inhibitors
GB0608098D0 (en) Formulation
PT2069335E (pt) Derivados de piridin-3-ilo como agentes imunomoduladores
SI1888580T1 (sl) Pirido d pirimidini uporabni kot inhibitorjiHCV in postopki za njihovo pripravo
IL210822A0 (en) Tri-cyclic pyrazolopyridine kinase inhibitor compounds, compositions comprising the same and uses thereof
AP2453A (en) Pyrazolo(3,4-B) pyridine derivatives as phosphodiesterase inhibitors
IL198462A0 (en) Diazepane-acetamide derivatives as selective 11??-hsd1 inhibitors
EP1993535A4 (en) THIAZOLONE AS A PI3 KINASE INHIBITOR
IL202769A0 (en) 6-PHENYL - 1H - IMIDAZO [4,5-c] PYRIDINE - 4 - CARBONITRILE DERIVATIVES AS CATHEPSIN INHIBITORS
ZA200805566B (en) 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives as cathepsin K and S inhibitors
ZA200706672B (en) 2,4-Diamino-pyridopyrimidine derivatives and their use as mTOR inhibitors
EP1993537A4 (en) THIAZOLONES AS INHIBITORS OF P13-KINASES
EP1993536A4 (en) THIAZOLONES AS INHIBITORS OF P13-KINASES
EP1996191A4 (en) THIAZOLONE AS A PI3 KINASE INHIBITOR
GB0625095D0 (en) Formulation
GB0625312D0 (en) Formulation